# WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)

> **NCT00769938** · PHASE4 · COMPLETED · sponsor: **R&D Cardiologie** · enrollment: 573 (actual)

## Conditions studied

- Anticoagulants
- Platelet Aggregation Inhibitors
- Stents
- Atrial Fibrillation

## Interventions

- **DEVICE:** PCI (percutaneous coronary intervention)

## Key facts

- **NCT ID:** NCT00769938
- **Lead sponsor:** R&D Cardiologie
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2012-08
- **Final completion:** 2012-08
- **Target enrollment:** 573 (ACTUAL)
- **Last updated:** 2013-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00769938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00769938, "WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00769938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*